What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.


Feb. 1

Weekly Gain

My Watchlist

Furiex Pharmaceuticals (NASDAQ: FURX)




Skyworks Solutions (NASDAQ:SWKS)




Pitney Bowes (NYSE:PBI)




Navidea Biopharmaceuticals (NYSEMKT:NAVB)








Source: Barron's.

Furiex Pharmaceuticals soared after receiving regulatory approval for a diabetes treatment that it is licensing to Takeda Pharmaceuticals. Furiex now stands to collect a $25 million payment for Takeda as well as ongoing royalties.

Skyworks Solutions rose after posting better-than-expected results. The company also issued upbeat guidance for its current quarter, and that's where the real surprise came. Skyworks is an iPhone supplier, and many investors had assumed that the company would struggle if the iPhone loses ground to cheaper devices.

Pitney Bowes' stock wasn't marked "return to sender" after posting strong quarterly results. Sure, seeing earnings plummet 57% on a 1% top-line dip isn't "strong" on an absolute basis. However, it's all relative on Wall Street. Analysts were expecting the metered mail giant to fare worse than it actually did.

When financial advisory services provider Burrill & Co. issued a bullish note on Navidea two weeks ago, our own Rich Smith was still concerned about the company's liquidity. Its promising Lymphoseek drug could receive regulatory approval later this year, but did it have enough money to see it through? Well, that problem appears to have taken care of itself.

The biotech announced on Wednesday that it was raising nearly $5 million by selling a little more than 1.5 million shares. Investors often bid down stocks after dilutive secondary offerings, but this helps Navidea fund ongoing operations until it can get its treatment on the market.

SUPERVALU checked out after the grocer set the interest rate that it will have to shell out in taking on $2.4 million in debt to support the sale of some of its supermarkets to a private equity group. The rate may be high, but investors appear relieved to have a little more clarity here.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.